Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis

Background: The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC) have been widely used in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS). However, few direct clinical trials have been carried out to compare the efficacy and adverse ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jiale, Ge, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416074/
https://www.ncbi.nlm.nih.gov/pubmed/34483903
http://dx.doi.org/10.3389/fphar.2021.701690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416074/
https://www.ncbi.nlm.nih.gov/pubmed/34483903
http://dx.doi.org/10.3389/fphar.2021.701690

Ejemplares similares